Dr Christopher Rowe
School of Medicine and Public Health
I am an Adult Endocrinologist at the John Hunter Hospital and early-career clinician-researcher at the University of Newcastle and the Hunter Medical Research Institute.
My primary area of research relates to thyroid nodules and thyroid cancer, although I am active across a wide range of projects in diabetes, pregnancy and endocrinology in the basic and clinical spheres.
My current doctoral studies through the University of Newcastle School of Medicine and Public Health are investigating new diagnostic and therapetic targets for thyroid cancer. In particular, our group is examining the utility of the TSH receptor as a specific theranostic marker for drug delivery, in collaboration with the John Hunter Hospital Thyroid Cancer Multidisciplinary Team, the Hunter Cancer Biobank and Pathology North (Hunter). I am also collaborating with Professor Hubert Hondermarck in the School of Biomedical Sciences and Pharmacy to study the role of neurotrophins as biomarkers and therapeutic targets in thyroid malignancy.
I am active in a number of clinical research projects studying the impact of visceral fat on insulin resistance in Type 1 and Type 2 Diabetes, and therapeutic strategies to mitigate this.
I am a current recipient of a Clinical Research Fellowship (Hunter New England Local Health District), and my recent research has been supported by the Hunter Cancer Research Alliance, Avant Mutual Group, the University of Newcastle, and the John Hunter Hospital Charitable Trust.
- Bachelor of Medicine, Bachelor of Surgery (Hons), University of New South Wales
- Bachelor of Science (Medicine), University of New South Wales
- Diabetes Mellitus
- insulin resistance
Fields of Research
|110901||Autonomic Nervous System||20|
|110102||Medical Biochemistry: Carbohydrates||20|
Australian Diabetes Society Travel Grant (Outstanding Abstract)
Australian Diabetes Society (ADS)
Australasian Diabetes in Pregnancy Society Travel Grant (Outstanding Abstract)
Australian Diabetes in Pregnancy Society (ADIPS)
Endocrine Society (USA) Travel Grant (Outstanding Abstract)
The Endocrine Society
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (8 outputs)
Gao F, Griffin N, Faulkner S, Rowe CW, Williams L, Roselli S, et al., 'The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung', SCIENTIFIC REPORTS, 8 (2018) [C1]
Rowe CW, Putt E, Brentnall O, Gebuehr A, Allabyrne J, Woods A, Wynne K, 'An intravenous insulin protocol designed for pregnancy reduces neonatal hypoglycaemia following betamethasone administration in women with gestational diabetes.', Diabet Med, (2018)
Faulkner S, Jobling P, Rowe CW, Rodrigues Oliveira SM, Roselli S, Thorne RF, et al., 'Neurotrophin Receptors TrkA, p75
© 2018 American Society for Investigative Pathology Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear.... [more]
© 2018 American Society for Investigative Pathology Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear. In this study, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75NTR, and the proneurotrophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and normal thyroid tissues (n = 62). TrkA was detected in 20% of thyroid cancers, compared with none of the benign samples (P = 0.0007). TrkA expression was independent of histologic subtypes but associated with lymph node metastasis (P = 0.0148), suggesting the involvement of TrkA in tumor invasiveness. Nerves in the tumor microenvironment were positive for TrkA. p75NTR was overexpressed in anaplastic thyroid cancers compared with papillary and follicular subtypes (P < 0.0001). Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P < 0.0001). Neurotrophin receptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels. Functional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against TrkA, p75NTR, and sortilin decreased cell survival and cell migration through decreased SRC and ERK activation. Together, these data reveal TrkA, p75NTR, and sortilin as potential therapeutic targets in thyroid cancer.
Rowe CW, Arthurs S, O'Neill CJ, Hawthorne J, Carroll R, Wynne K, Bendinelli C, 'High-dose preoperative cholecalciferol to prevent post-thyroidectomy hypocalcaemia: a randomized, double-blind placebo-controlled trial.', Clin Endocrinol (Oxf), (2018)
Rowe CW, Paul JW, Gedye C, Tolosa JM, Bendinelli C, McGrath S, Smith R, 'Targeting the TSH receptor in thyroid cancer', Endocrine-Related Cancer, 24 R191-R202 (2017) [C1]
© 2017 Society for Endocrinology Printed in Great Britain. Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The exis... [more]
© 2017 Society for Endocrinology Printed in Great Britain. Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid-stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients. Furthermore, TSHR has been recently re-conceived as a selective target for residual metastatic thyroid cancer, with pilot data demonstrating effective targeting of nanoparticles to thyroid cancers using this receptor as a target. This review examines the evidence for TSHR signaling as an oncogenic pathway and assesses the evidence for ongoing TSHR expression in thyroid cancer metastases. Priorities for further research are highlighted.
Rowe CW, Haider AS, Viswanathan D, Jones M, Attia J, Wynne K, Acharya S, 'Insulin resistance correlates with maculopathy and severity of retinopathy in young adults with Type 1 Diabetes Mellitus', Diabetes Research and Clinical Practice, 131 154-160 (2017) [C1]
© 2017 Elsevier B.V. Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-se... [more]
© 2017 Elsevier B.V. Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-sectional study at a regional Australian tertiary hospital. Retinal pathology, assessed by colour fundus photography, was correlated with two surrogate measures of IR: estimated Glucose Disposal Rate (eGDR) and Insulin Sensitivity Score (ISS), where lower scores reflect greater IR. Results 107 patients were recruited, with mean age 24.7¿years, 53% male, and mean duration of disease 10.8¿years. Mean eGDR scores (5.6¿vs 8.0 p¿<¿0.001) and ISS (4.7¿vs 7.9, p¿<¿0.001) were lower in subjects having at least moderate non-proliferative diabetic retinopathy (NPDR; relative to nil/mild-NPDR). Similarly, mean eGDR (4.2¿vs 6.2, p¿=¿0.001) and ISS (3.8¿vs 6.1, p¿=¿0.003) were lower in patients with maculopathy. Multivariate logistic regression modelling was used to control for confounding. For retinopathy severity, a unit increase in eGDR or ISS (representing lower IR) was associated with a 50% decrease in odds of moderate-NPDR or worse (eGDR OR 0.5, 95%CI 0.32¿0.77, p¿=¿0.002; ISS OR 0.49, 95%CI 0.29¿0.84, p¿=¿0.01). A unit increase in eGDR or ISS was associated with a 46¿56% decrease in odds of maculopathy (eGDR OR 0.54, 95%CI 0.37¿0.81, p¿=¿0.003; ISS OR 0.44, 95%CI 0.22¿0.88, p¿=¿0.02). Conclusions IR correlates with more severe retinopathy in young adults with Type 1¿DM. This is the first description of a correlation between IR and maculopathy in Type 1¿DM, warranting further evaluation. Prospective studies examining whether reducing IR can improve microvascular complications are required.
|Show 5 more journal articles|
Conference (20 outputs)
Rowe C, Dill T, Clarke M, Paul J, Gedye C, King S, Hondermarck H, 'A methodology for validating automated digital whole-slide analysis of immunohistochemical biomarkers using open source software (QuPath).', Newcastle, Australia (2018)
|2018||Kuehn J, Rowe CW, Amico F, Ward A, Bendinelli C, 'Management of¿an intrathyroidal cystic parathyroid gland¿with post-traumatic haemorrhagic transformation¿causing¿acute airway compromise', Adelaide, Australia (2018)|
|2018||Croker E, Chew C, Weigner J, Bendinelli C, McGrath S, Rowe CW, 'The whole is greater than the sum of its parts: synthesised triple-assessment of thyroid nodules optimises pre-operative risk-stratification.', Adeladie (2018)|
Pradeepan S, Pullen SJ, Viljevac N, Murdoch T, Bone E, Stormer J, et al., 'VLED is an effective real-life treatment for severe complex obesity, and improves obstructive sleep apnoea', JOURNAL OF SLEEP RESEARCH, Brisbane, AUSTRALIA (2018)
|Show 17 more conferences|
Grants and Funding
|Number of grants||5|
Click on a grant title below to expand the full details for that specific grant.
20181 grants / $397,528
Hunter Cancer Biobank$397,528
Funding body: NSW Health Pathology - Pathology North
|Funding body||NSW Health Pathology - Pathology North|
|Project Team||Professor Marjorie Walker, Laureate Professor Rodney Scott, Conjoint Professor Stephen Ackland, Mrs Susan Goode, Associate Professor Pradeep Tanwar, Doctor Nikki Verrills, Professor Hubert Hondermarck, Doctor Simon King, Mr Ricardo Vilain, Associate Professor Nikola Bowden, Doctor Kelly Kiejda, Associate Professor Simon Keely, Doctor Christopher Rowe|
|Type Of Funding||C2220 - Aust StateTerritoryLocal - Other|
20171 grants / $15,000
Funding body: Hunter Cancer Research Alliance (HCRA)
|Funding body||Hunter Cancer Research Alliance (HCRA)|
Christopher Rowe, Hubert Hondermarck, Roger Smith, Shaun McGrath, Simon King, Marjorie Walker, John Attia
|Scheme||HCRA Implementation Flagship program|
|Type Of Funding||Grant - Aust Non Government|
20162 grants / $40,000
Funding body: AVANT Mutual Group
|Funding body||AVANT Mutual Group|
Christopher Rowe, Jonathan Paul, Jorge Tolosa, Roger Smith
|Scheme||Doctors in Training Scholarship Scheme|
|Type Of Funding||Grant - Aust Non Government|
Funding body: Hunter New England Health
|Funding body||Hunter New England Health|
|Scheme||Clinical Research Fellowship|
|Type Of Funding||Other Public Sector - State|
20151 grants / $20,000
Funding body: John Hunter Charitable Trust
|Funding body||John Hunter Charitable Trust|
Christopher Rowe, Shamasunder Acharya, Lin Perry, Katie Wynne
|Scheme||John Hunter Charitable Trust Grant|
|Type Of Funding||Other Public Sector - State|